Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: Dél-Korea2. fázis

Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory Polymyositis or Dermatomyositis

A legfontosabb adatok

Ki végzi
Paean Biotechnology Inc.
Hol
Gwangmyeong és Seoul (Dél-Korea)Mind a 5 helyszín megnézése
Azonosító
Állapot
Toborzás még nem indult
Fázis
2. fázis
Résztvevők
36 fő, tervezett
Kezdés
2025. dec.
Várható befejezés
2027. ápr.
A vizsgálat típusa
Beavatkozással járó, 3 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • placebo
  • PN-101
A regiszteradat frissítve
2025. augusztus 14.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with polymyositis or dermatomyositis whose current treatment does not work well enough or causes side effects. Each person gets one dose of PN-101 or a placebo (dummy treatment).

Életkor
19 years or older
Nem
All sexes can join
A betegség stádiuma
Active polymyositis or dermatomyositis with weakness in muscles close to the body center, confirmed by electromyography (EMG). MMT-8 muscle score under 125/150 and at least 2 other signs of active disease.
Korábbi kezelés
People must now be taking steroids and/or immunosuppressants or immunomodulators for the disease without enough benefit, or be unable to continue them because of side effects. People must be doing exercise or physical therapy and keep it the same.
Biomarker vagy leletérték
Blood creatine kinase (CK) at least 1.3 × upper limit of normal, or a positive myositis-specific antibody (MSA) test.

A részvétel fő kizáró okai

  • Clear lasting muscle damage (myositis damage index 5 or more), or disease that started before age 10
  • Severe breathing muscle weakness or lung disease, other muscle diseases, or other autoimmune diseases
  • Cancer within 5 years, surgery within 12 weeks, active hepatitis B or C, or HIV positive
  • Moderate or severe heart failure, or poor kidney, liver or blood test results
  • Pregnant or breastfeeding, or not willing to use birth control for 36 weeks after the dose

A regiszter feltételei, szó szerint

Mind a 18 feltétel megnézéseKevesebb

Ki vehet részt

  • Adult aged 19 years or more
  • A subject who is diagnosed with polymyositis or dermatomyositis and satisfies all of the followings:; Clinical profile: Slowly progressing clinical profile with symmetrical and apparent muscular weakness confirmed at the proximal muscle (in case of dermatomyositis, clinical findings related with characteristic skin symptoms*); Gottron's papules or sign, erythema purpura, poikiloderma, calcinosis cutis, etc; Serum test: Serum creatine kinase (CK) elevated (CK ≥ 1.3 × upper limit of normal (ULN)) or serum myositis-specific antibodies (MSA) positive; Electromyography (EMG): Presence of a finding that indicates myopathy
  • Baseline (prior to the investigational product administration) manual muscle testing-8 (MMT-8) result < 125/150 (bilaterally), and at least 2 of the following International Myositis and Clinical Studies Group (IMACS) core set results; Physician global disease activity [visual analogue scale (VAS)] ≥ 2 cm; Patient global disease activity [VAS] ≥ 2 cm; Health assessment questionnaire (HAQ) disability assessment ≥ 0.25; 1 or more items with the serum muscle enzyme > 1.3 × ULN; Global extramuscular disease activity [VAS] > 1 cm
  • Individuals who are currently receiving glucocorticosteroids and/or steroid-sparing drugs such as immunosuppressants or immunomodulators for the treatment of polymyositis or dermatomyositis but are deemed to have an inadequate response to treatment, or who are unable to continue existing treatment due to drug-related adverse events or side effects (however, during the clinical trial, the dosage of steroids and immunosuppressants may be adjusted within 20% of the dose prior to the study participation)
  • Individuals who are receiving exercise or physical therapy and have agreed to maintain the same intensity and frequency of their current therapy
  • A subject who fully understands the trial and provided voluntary written consent to take part in the trial

Ki nem vehet részt

  • A subject who is determined to require prohibited concomitant treatment during the trial
  • Pregnant woman and lactating mother or woman of childbearing potential and man who is planning to have a child or not willing to practice acceptable contraception* for 36 weeks after the last dosing date *Hormonal contraception, intrauterine device or intrauterine system implant, surgical sterilization procedure/operation (vasectomy, tubal ligation, etc.)
  • Participation in other clinical trial and administration of an investigational product or application of an investigational device within 4 weeks or half-life x 5 (whichever is longer) prior to screening
  • A subject with the following medical history or surgical history; A surgical operation history within 12 weeks of screening; Malignant tumor within 5 years of screening (excluding a subject who passed 3 years or more from complete recovery of cervical cancer or skin squamous cell carcinoma)
  • A patient with severe respiratory muscular weakening or interstitial pulmonary disease (a patient who has no moderate or severe dyspnea and has stable interstitial pneumonia may participate)
  • A patient with the following comorbidity at screening; Acute viral infection or severe infection; Active hepatitis B (e.g.: HBsAg positive and HBV DNA detected) or hepatitis C (e.g.: Anti-HCV positive and HCV RNA [qualitatively] detective); Human Immunodeficiency virus (HIV) positive; Findings of muscular inflammation or myopathy other than the indication (inclusion body myositis (IBM), drug-induced myopathy, amyloid myopathy, myotonic dystrophy, etc.); Autoimmune disease such as rheumatoid arthritis (RA), systemic lupus erythematosus, psoriatic arthritis, etc. (however, in case of the overlap syndrome, a subject may participate if diseases other than inflammatory myositis are stable and myositis is thought to be due to inflammatory myositis.); Findings of cardiac disorder such as moderate or severe heart failure (New York Heart Association Class III/IV) or QT corrected interval prolonged; Serious disease that may affect this study, at the discretion of the investigator (neurological disorder, cardiovascular disorder, uncontrolled blood pressure or diabetes, etc.)
  • Hematological, renal and hepatic dysfunction based on the following laboratory findings at screening; Glomerular filtration rate (GFR)* < 45 mL/min *eGFR (mL/min/1.73m\^2) = 175 × (serum creatinine concentration (mg/dL))\^-1.154 × (age)\^-0.203 × (0.742 in female) [modification of diet in renal disease (MDRD) formula]; Hemoglobin < 10 g/dL; White blood cell (WBC) count < 3.0×10\^9/L; Absolute neutrophil count (ANC) < 1.5×10\^9/L (1500/mm\^3); Platelet count < 100×10\^9/L; AST and ALT > 2.5 × ULN (except for the elevation due to muscle enzyme at the discretion of the investigator); Alkaline phosphatase (ALP) > 2.5 × ULN; Total bilirubin > 1.5 × ULN (> 3 × ULN, in case of Gilbert's syndrome); Thyroid stimulating hormone level exceeding the normal range (however, if the level exceeds the normal range due to the study indication at the discretion of the investigator, the subjects are allowed to enroll.)
  • Patients diagnosed with polymyositis or dermatomyositis before the age of 10 (Juvenile PM or Juvenile DM)
  • Subjects who meet any of the following criteria will not be eligible to participate in this clinical trial:
  • A subject with clear muscular damage, with the VAS-based myositis damage index (MDI) of ≥ 5 at screening
  • A subject with a difficulty in the efficacy assessment including the muscular strength assessment during the trial
  • A subject who is otherwise ineligible for this trial, at the discretion of the investigator

Helyszínek itt: Dél-Korea

  • Chung-Ang University Gwang Myeong HospitalGwangmyeong, Dél-KoreaContact: Eun Hye Park, MD (principal investigator)Toborzás még nem indult
  • Chung ang University HospitalSeoul, Dél-KoreaToborzás még nem indult
  • Kyung Hee University Medical CenterSeoul, Dél-KoreaContact: Yeonah Kim, MD (principal investigator)Toborzás még nem indult
  • Seoul National UniversitySeoul, Dél-KoreaContact: Eunyoung Lee, MD (principal investigator)Toborzás még nem indult
  • Soon Chun Hyang University Hospital SeoulSeoul, Dél-KoreaContact: Hyunsook Kim, MD (principal investigator)Toborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

The efficacy of PN-101 in subjects with polymyositis or dermatomyositis will be evaluated at Week 12 using IMACS-TIS in comparison with the placebo control group. The safety and efficacy will be evaluated following administration of PN-101 to subjects with polymyositis or dermatomyositis, in comparison with the placebo group

A vizsgálat 3 csoportja

  • Placebo GroupPlacebo, összehasonlításként

    Kezelés: placebo

  • 300 ug of PN-101 groupA vizsgált kezelés

    Kezelés: PN-101

  • 600 ug of PN-101 groupA vizsgált kezelés

    Kezelés: PN-101

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Prospective, Multi-center, Randomized, Double-blinded, Placebo-controlled, Parallel, Phase 2 Trial to Evaluate the Efficacy, Safety of PN-101(Mitochondria Isolated From Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells) Single Dose in Patients With Refractory Polymyositis or Dermatomyositis
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2025. augusztus 14.